Selective transduction of mature dc in human skin and lymph nodes by cd80/cd86-targeted fiber-modified adenovirus-5/3

Journal of Immunotherapy

Volumn 32, Issue 9, 2009, Pages 895-906

  De Gruijl, Tanja D ^b,c   Van De Ven, Rieneke ^a   Lindenberg, Jelle J ^b   Oosterhoff, Dinja ^b   Van Den Tol, M Petrousjka ^b   Rosalia, Rodney A ^b   Murakami, Miho ^d   Everts, Maaike ^d   Scheffer, George L ^a   Scheper, Rik J ^a   Curiel, David T ^d  

^a Departments of Pathology   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Division of Human Gene Therapy   (United States)

^d NONE

Author keywords

Ad5 3; Adenovirus; DC targeting; Human lymph node DC; Human skin DC

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; B7 ANTIGEN; CD38 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; T6 ANTIGEN;

ADENOVIRUS; ADENOVIRUS 3; ADENOVIRUS 5; ARTICLE; BONE MARROW CELL; CELL MATURATION; CHIMERA; CONTROLLED STUDY; DENDRITIC CELL; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LANGERHANS CELL; LYMPH NODE; LYMPHATIC DRAINAGE; MELANOMA; PRIORITY JOURNAL; SKIN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADENOVIRIDAE; ANTIGENS, CD80; ANTIGENS, CD86; CELL LINE; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; GENETIC VECTORS; HUMANS; LYMPH NODES; SKIN; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 70350528710     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b56deb     Document Type: Article

References (40)

1. Sumida SM, Truitt DM, Kishko MG, et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol. 2004;78:2666-2673.
2. Ni S, Bernt K, Gaggar A, et al. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther. 2005; 16:664-677.
3. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet. 2007;8:573-587.
4. de Gruijl TD, Ophorst OJ, Goudsmit J, et al. Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells. J Immunol. 2006;177:2208-2215.
5. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003;9: 1408-1412.
6. Wang H, Liaw YC, Stone D, et al. Identification of CD46 Binding Sites within the Adenovirus Serotype 35 Fiber Knob. J Virol. 2007;81:12785-12792.
7. Liszewski MK, Kemper C, Price JD, et al. Emerging roles and new functions of CD46. Springer Semin Immunopathol. 2005; 27:345-358.
8. Short JJ, Pereboev AV, Kawakami Y, et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology. 2004;322:349-359.
9. Brown K, Gao W, Alber S, et al. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J Immunol. 2003;171:6875-6882.
10. Gaffal E, Schweichel D, Tormo D, et al. Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells. Eur J Cell Biol. 2007; 86:817-826.
11. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72:9706-9713.
12. Wu H, Seki T, Dmitriev I, et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther. 2002;13:1647-1653.
13. Segerman A, Atkinson JP, Marttila M, et al. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol. 2003;77:9183-9191.
14. Sirena D, Lilienfeld B, Eisenhut M, et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol. 2004;78:4454-4462.
15. Marttila M, Persson D, Gustafsson D, et al. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol. 2005;79:14429-14436.
16. Fleischli C, Sirena D, Lesage G, et al. Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. J Gen Virol. 2007; 88:2925-2934.
17. Masterson AJ, Sombroek CC, de Gruijl TD, et al. MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood. 2002;100:701-703.
18. van de Ven R, de Jong MC, Reurs AW, et al. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J Immunol. 2006;176:5191-5198.
19. Shayakhmetov DM, Li ZY, Ternovoi V, et al. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol. 2003;77:3712-3723.
20. Maizel JV Jr, White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology. 1968;36:115-125.
21. Vuylsteke RJ, van Leeuwen PA, Meijer S, et al. Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol. 2002; 161:19-26.
22. de Gruijl TD, Luykx-de Bakker SA, Tillman BW, et al. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol. 2002;169: 5322-5331.
23. Santegoets SJ, Masterson AJ, van der Sluis PC, et al. A CD34+ human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+ CD11b+ Langerhans cell precursor. J Leukoc Biol. 2006;80:1337-1344.
24. de Gruijl TD, Sombroek CC, Lougheed SM, et al. A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracu-taneous cytokine balance. J Immunol. 2006;176:7232-7242.
25. Short JJ, Vasu C, Holterman MJ, et al. Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res. 2006;122:144-153.
26. DiPaolo N, Ni S, Gaggar A, et al. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination. Mol Ther. 2006;13:756-765.
27. Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38:1404-1413.
28. Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, et al. Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol. 2005;167:1301-1307.
29. Molenkamp BG, van Leeuwen PA, Meijer S, et al. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res. 2007;13:2961-2969.
30. Sakurai F, Akitomo K, Kawabata K, et al. Downregulation of human CD46 by adenovirus serotype 35 vectors. Gene Ther. 2007;14:912-919.
31. Seya T, Hirano A, Matsumoto M, et al. Human membrane cofactor protein (MCP, CD46): multiple isoforms and functions. Int J Biochem Cell Biol. 1999;31:1255-1260.
32. Stoff A, Rivera AA, Banerjee NS, et al. Strategies to enhance transductional efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds. Wound Repair Regen. 2006;14:608-617.
33. Vuylsteke RJ, Molenkamp BG, Gietema HA, et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res. 2004;64:8456-8460.
34. Santegoets SJ, Bontkes HJ, Stam AG, et al. Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. J Immunol. 2008;180:4540-4549.
35. Toes RE, van der Voort EI, Schoenberger SP, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998;160:4449-4456.
36. Ophorst OJ, Kostense S, Goudsmit J, et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine. 2004;22:3035-3044.
37. Ophorst OJ, Radosevic K, Havenga MJ, et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun. 2006;74:313-320.
38. Holterman L, Vogels R, van der Vlugt R, et al. Novel replication- incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol. 2004;78:13207-13215.
39. Wu H, Dmitriev I, Kashentseva E, et al. Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol. 2002;76:12775-12782.
40. Korokhov N, Noureddini SC, Curiel DT, et al. A Single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Mol Pharm. 2005; 2:218-223.